NCT00655980

Brief Summary

In this study, we want to find out if laughing gas (nitrous oxide) leads to a higher rate of cardiac complications after surgery in patients with a specific genetic profile (mutations in the MTHFR gene) and if this risk can be prevented by giving patients vitamin B12 and folate during surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
687

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2008

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2008

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 10, 2008

Completed
8.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
3.8 years until next milestone

Results Posted

Study results publicly available

October 1, 2020

Completed
Last Updated

October 1, 2020

Status Verified

September 1, 2020

Enrollment Period

8.8 years

First QC Date

April 4, 2008

Results QC Date

April 23, 2018

Last Update Submit

September 8, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Myocardial Ischemia

    Measured by serial troponin and ECG

    first 3 postoperative days

Secondary Outcomes (1)

  • Non-fatal MI

    30 day postoperative

Study Arms (3)

Treatment

EXPERIMENTAL

Vitamin B12 and folic acid

Drug: Vitamin B12 and folic acid

Comparator

PLACEBO COMPARATOR

Nitrous oxide and placebo

Drug: Nitrous oxide and placebo

Standard of care

OTHER

standard of care

Other: standard of care

Interventions

1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion

Treatment
Standard of care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients; age \>18 yrs, ASA III-IV
  • Previously diagnosed coronary artery disease or at risk for coronary artery disease
  • Scheduled for major surgery (\>2 hrs)

You may not qualify if:

  • Patients not expected to live past 24 hours (ASA 5)
  • Patients with significant pulmonary disease requiring supplemental oxygen
  • Patients taking supplemental vitamin B12 or folate
  • Contraindication against N2O (pneumothorax, mechanical bowel obstruction, middle ear occlusion, laparoscopic surgery, raised intracranial pressure)
  • Hypersensitivity to cobalamins
  • Leber's disease (hereditary optic nerve atrophy) \[vitamin B12 interaction\]
  • Seizure disorder \[folate interference\]

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barnes-Jewish Hospital

St Louis, Missouri, 63110, United States

Location

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Vitamin B 12Folic AcidNitrous OxideStandard of Care

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

CorrinoidsTetrapyrrolesPyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingMacrocyclic CompoundsPolycyclic CompoundsPterinsPteridinesHeterocyclic Compounds, 2-RingNitrogen OxidesGasesInorganic ChemicalsNitrogen CompoundsOxidesOxygen CompoundsQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Results Point of Contact

Title
Principal Investigator
Organization
University of Chicago Medicine

Study Officials

  • Peter Nagele, MD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2008

First Posted

April 10, 2008

Study Start

February 1, 2008

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

October 1, 2020

Results First Posted

October 1, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations